



Published in final edited form as:

Angew Chem Int Ed Engl. 2016 July 18; 55(30): 8639–8642. doi:10.1002/anie.201603420.

Elucidation of the Covalent and Tertiary Structures of Biologically Active Ts3 Toxin

Dr. Bobo Dang,

Department of Chemistry, Department of Biochemistry & Molecular Biology, Institute for Biophysical Dynamics, University of Chicago Chicago, IL 60637

Dr. Tomoya Kubota,

Department of Biochemistry & Molecular Biology, University of Chicago, Chicago, IL 60637

Dr. Kalyaneswar Mandal,

Department of Chemistry, Department of Biochemistry & Molecular Biology, Institute for Biophysical Dynamics, University of Chicago Chicago, IL 60637

Prof. Dr. Ana M. Correa,

Department of Biochemistry & Molecular Biology, University of Chicago, Chicago, IL 60637

Prof. Dr. Francisco Bezanilla, and

Department of Biochemistry & Molecular Biology, Institute for Biophysical Dynamics, University of Chicago Chicago, IL 60637

Prof. Dr. Stephen B. H. Kent*

Department of Chemistry, Department of Biochemistry & Molecular Biology, Institute for Biophysical Dynamics, University of Chicago Chicago, IL 60637

Abstract

Ts3 is an alpha scorpion toxin from the venom of the Brazilian scorpion *Tityus serrulatus*. Ts3 binds to the domain IV voltage sensor of voltage-gated sodium channels (Na_v) and slows down their fast inactivation. The covalent structure of Ts3 toxin is uncertain, and the structure of the folded protein molecule is unknown. Here we report the total chemical synthesis of four candidate Ts3 toxin protein molecules and the results of structure-activity studies that enabled us to establish the covalent structure of biologically active Ts3 protein molecule. We also report synthesis of the mirror image form of Ts3 toxin protein, and the use of racemic protein crystallography to determine the folded (tertiary) structure of biologically active Ts3 toxin by X-ray diffraction.

Keywords

Ts3 toxin; chemical protein synthesis; racemic protein crystallography

Ts3 is an alpha scorpion toxin protein natural product isolated from the venom of the Brazilian scorpion *Tityus serrulatus*^[1]. Alpha-scorpion toxins belong to the family of Nav

* skent@uchicago.edu.

Supporting information for this article is given via a link at the end of the document.

channel gating modifier proteins, and they mainly bind to the loop connecting S3 and S4 in Na_v domain IV.^[2,3] Upon binding to the Na_v channels, these toxins inhibit the fast inactivation of Na_v channels without dramatically affecting the activation of the channels.^[4-8]

Prior to the work in this paper, there was no X-ray or NMR structure of the Ts3 protein. Furthermore, there is confusion in the literature about the C-terminus of the Ts3 polypeptide chain: some papers stated that the active Ts3 toxin had 62 amino acid residues,^[9] while others believed it had 64 amino acid residues.^[10,11] From analysis of the gene sequence, Martin-Eauclaire *et al.* proposed that the 64 residue Ts3 toxin polypeptide chain should terminate as the carboxamide.^[10] In the same paper, they also suggested there could be three different C-terminal candidates for the correct sequence of the Ts3 toxin protein.^[10] To resolve this confusion and to determine the amino acid sequence and covalent structure of active Ts3 toxin, our first task was to prepare the three proposed Ts3 polypeptide chains together with the precursor polypeptide chain Ts3(1-67) (Scheme 1a), in order to determine which if any of these polypeptides folds to form biologically active Ts3 toxin protein.

We have previously reported total synthesis of the Ts1 toxin protein molecule,^[12] but that experience was of limited use for the current work. Although isolated from the same scorpion venom, Ts3 toxin and Ts1 toxin are very different protein molecules: they have distinct biological activities - Ts1 is a *beta*-scorpion toxin while Ts3 is an *alpha*-scorpion toxin; there is little sequence homology between the two polypeptide chains (only 16/53 conserved non-Cys residues [Figure 1]); and, Ts3 has much greater structural ambiguity at its C-terminus than was the case with Ts1 toxin. Although Ts3 toxin and Ts1 toxin do share a conserved pattern of eight Cys residues in the amino acid sequence of their polypeptide chains (Figure 1), it has been shown that, even where the pattern of Cys residues is conserved scorpion venom proteins can have distinct tertiary structures.^[13]

Total chemical synthesis of the candidate Ts3 polypeptide chains was carried out using a modular approach as shown in Scheme 1b. Native chemical ligation sites were chosen at -Tyr²³-Cys²⁴- and -Tyr⁴⁶-Cys⁴⁷- so that, after preparation of the C-terminal peptide variants, the peptide segments used were of similar length (*viz.* 23; 23; and 16, 18, 20, or 21 amino acids). Peptide segments were synthesized as described in the SI (Figures S1-9). Four distinct C-terminal peptide segments were prepared by native chemical ligation of Thz⁴⁷-Lys⁶¹-thioester to the corresponding C-terminal Cys-peptide, or cysteine (Scheme 1b). Analytical data for the preparation by native chemical ligation of the full-length Ts3(1-64)-CONH₂ polypeptide chain are shown in Figure 2a. Synthetic manipulations (see SI) for making each of the four full-length candidate Ts3 polypeptide chains were essentially similar (Figures S10-12).

Folding the synthetic Ts3 polypeptide chains turned out to be extremely challenging. Conventional conditions that used a thiol-disulfide redox couple, together with a low concentration of the chaotrope Gu·HCl to keep misfolded/mispaired disulfide intermediates in solution, did not produce any discrete folded product. Nor did the folding conditions we had previously developed for Ts1.^[12] Addition of 20% v/v DMSO to the redox buffer gave acceptable yields of discrete folded products, of mass 8 Da less than that of the

corresponding polypeptide chains, indicating the formation of 4 disulfide bonds. After careful optimization, the final folding conditions used were: [polypeptide] 0.02 mg/mL; 2.0 mM GSH/ 1.0 mM GSSG; 0.5 M L-arginine·HCl; 1.0 mM EDTA; 0.1 M Tris, 20% DMSO, pH 8.5; room temperature. Data for the folding of Ts3(1-64)-CONH₂ is shown in Figure 2b. Using these conditions, we were able to fold all four Ts3 candidate polypeptide chains, with concomitant formation of 4 disulfides in each case as shown by the loss of 8 Da. Analytical LCMS data for the four variant synthetic candidate Ts3 proteins are shown in Figure S13.

Structure-activity profiles of the four candidate Ts3 protein molecules were evaluated by the fast inactivation decay rate of sodium currents recorded from heterologously expressed at skeletal muscle voltage-gated sodium channel (rNa_v1.4) in the presence of 210 nM of each protein (5 min incubation at a holding potential of -90 mV) (Figure 3). Ts3(1-64)-CONH₂ protein showed obvious disruption the rNa_v1.4 fast inactivation (Figure 3a), while the other three protein molecules showed minimal effects. on treatment with Ts3(1-64)-CONH₂ protein, fast inactivation decay of rNav1.4 became slower in a dose-dependent manner (Figure 3b). The effect saturated at concentrations between 210-2100 nM, consistent with previous reports using Ts3 toxin isolated from scorpion venom.^[8] Ts3(1-64)-CONH₂ protein can thus be presumed to be the principal toxic component of natural Ts3 toxin isolated from scorpion venom.

With the covalent structure of biologically active Ts3 protein in hand, we set out to determine its folded structure by X-ray crystallography. Crystallization of L-Ts3(1-64)-CONH₂ toxin protein was problematic, so racemic protein crystallization was used.^[14-16] Preparation of the D-Ts3(1-64)-CONH₂ polypeptide chain and its folding were as described for the L-protein enantiomer. (Figures S14-16). Crystallization trials using the Hampton Index (HR2-144) screen and a racemic mixture at 10 mg/mL (5 mg/mL of L-Ts3(1-64)-CONH₂ toxin plus 5 mg/mL of D-Ts3(1-64)-CONH₂ protein) produced diffraction-quality crystals from a single condition [0.1 M BIS-TRIS pH 6.5, 28% w/v Polyethylene glycol monomethyl ether 2,000 at 19 °C] after three weeks.

Diffraction data were collected from the racemic D/L-protein crystal at an energy level of 12.6 keV using the NE-CAT beamline 24-ID-E at the Advanced Photon Source at Argonne National Laboratory. Reasonably complete diffraction data were collected to a resolution of 1.93 Å. Diffraction intensity statistics revealed that the race mic D/L-protein crystallized in space group P1<bar>, with one enantiomer in the asymmetric Unit. The X-ray structure of racemic D/L-Ts3(1-64)-CONH₂ protein was solved by molecular replacement^[17] using the scorpion toxin LQH-alpha-IT (PDB ID: 2ASC) as a search model. The final model was refined to a crystallographic R-factor of 0.26 (R-free 0.30) using Phenix.^[18] Note that this centrosymmetric R factor corresponds to a conventional R factor that is ~33% smaller (i.e. R-factor ~0.20).^[19] The packing of D-Ts3(1-64)-CONH₂ and L-Ts3(1-64)-CONH₂ proteins in the unit cell is shown in Figure 4a, with the two enantiomeric molecules in the unit cell.

As shown by comparison with the structures of the prototypical alpha scorpion toxins LQH-α-IT and Aah2 (PDB ID: 1AHO) the Ts3(1-64)-CONH₂ protein molecule has a typical alpha scorpion toxin fold made up of an α-helix (residues 21-31) packed against a three-stranded anti-parallel β-sheet (residues 2-4, 35-39, 44-50) (Figure 4b). Alpha scorpion

toxins have two surfaces that interact with the Na_v channel: a “Core domain”, formed by loop residues that connect the secondary structure elements, and an “NC-domain”, formed by a five-residue turn near the N-terminus (residues 8-12) and the C-terminal region.^[21] In the Core domain of Ts3, the Tyr¹⁹ side chain was found to overlap with the side chain of the functionally important Trp³⁸ of other alpha scorpion toxins (Figure 4c). The NC-domain of Ts3 is quite similar to the NC-domain of the other members of the alpha scorpion toxin family in terms of both structure (Figure 4d), and surface electrostatics. The C-terminal region of Ts3 and similar alpha-scorpion toxins is heavily populated with multiple positively charged residues. Side chains of conserved Asn¹¹ and Lys⁵⁷ of Ts3 form a hydrogen bonding network with the main chain amide at the C-terminus which, together with a disulfide bond at Cys⁶², holds the C-terminus in position for interacting with the sodium channel (Figure 4e).

A robust total synthesis of the Ts3 protein molecule using a modular synthetic strategy has enabled us to prepare the four suggested covalent structures for Ts3 toxin. Correlating biological activity measurements with the known structures of these synthetic proteins verified the covalent structure of biologically active Ts3 toxin. Using racemic protein crystallization, diffraction quality crystals of racemic Ts3 protein were obtained, and from the resulting X-ray diffraction data we determined the three-dimensional structure of biologically active Ts3 toxin. The covalent and tertiary structures of biologically active Ts3 toxin reported here constitute essential information for future work aimed at developing Ts3 protein as a biophysical probe of the Nav channel,^[22] in order to complement and extend the information obtained using labeled Ts1 neurotoxin.^[23]

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

This research was supported in part by funds from NIH Grants U54 GM087519, and R01-GM030376 to F. Bezanilla and by the American Heart Association (13POST14800031) to T. Kubota. Use of NE-CAT beamline 24-ID at the Advanced Photon Source is supported by the National Institute of General Medical Sciences from the National Institutes of Health (P41 GM103403). Use of the Advanced Photon Source is supported by the U.S. Department of Energy, Office of Basic Energy Sciences, under Contract No. DE-AC02-06CH11357.

References

1. Possani LD, Martin BM, Mochcamorales J, Svendsen I. *Carlsberg Res. Commun.* 1981; 46:195.
2. Rogers JC, Qu Y, Tanada TN, Scheuer T, Catterall WA. *J. Biol. Chem.* 1996; 271:15950. [PubMed: 8663157]
3. Benzinger GR, Kyle JW, Blumenthal KM, Hanck DA. *J. Biol. Chem.* 1998; 273:80. [PubMed: 9417050]
4. Catterall WA. *J. Biol. Chem.* 1977; 252:8660. [PubMed: 72754]
5. Couraud F, Rochat H, Lissitzky S. *Biochem. Biophys. Res. Commun.* 1978; 83:1525. [PubMed: 29635]
6. Kirsch GE, Skattebol A, Possani LD, Brown AM. *J. Gen. Physiol.* 1989; 93:67. [PubMed: 2536799]
7. Campos FV, Coronas FI, Beirão PSL. *Br. J. Pharmacol.* 2004; 142:1115. [PubMed: 15249424]
8. Campos FV, Chanda B, Beirao PS, Bezanilla F. *J. Gen. Physiol.* 2008; 132:251. [PubMed: 18663133]

9. Cologna CT, Marcussi S, Giglio JR, Soares AM, Arantes EC. *Protein Pept. Lett.* 2009; 16:920. [PubMed: 19689419]
10. Martin-Eauclaire MF, Céard B, Ribeiro AM, Diniz CR, Rochat H, Bougis PE. *FEBS Lett.* 1994; 342:181. [PubMed: 8143874]
11. Teixeira CE, Ifa DR, Corso G, Santagada V, Caliendo G, Antunes E, De Nucci G. *FASEB J.* 2003; 17:485. [PubMed: 12551849]
12. Dang B, Kubota T, Correa AM, Bezanilla F, Kent SBH. *Angew. Chem. Int. Ed. Engl.* 2014; 53:8970–8974. [PubMed: 24989851] *Angew. Chem.* 2014; 126:9116.
13. Saucedo AL, Flores-Solis D, Rodríguez de la Vega RC, Ramírez-Cordero B, Hernández-López R, Cano-Sánchez P, Noriega Navarro R, García-Valdés J, Coronas-Valderrama F, de Roodt A, Brieba LG, Domingos Possani L, del Rfo-Portilla F. *J. Biol. Chem.* 2012; 287:12321. [PubMed: 22238341]
14. Pentelute BL, Gates ZP, Tereshko V, Dashnau JL, Vanderkooi JM, Kossiakoff AA, Kent SBH. *J. Am. Chem. Soc.* 2008; 130:9695. [PubMed: 18598029]
15. Dang B, Kubota T, Mandal K, Bezanilla F, Kent SBH. *J. Am. Chem. Soc.* 2013; 135:11911. [PubMed: 23919482]
16. Yeates TO, Kent SBH. *Annu. Rev. Biophys.* 2012; 41:41. [PubMed: 22443988]
17. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. *J. Appl. Crystallogr.* 2007; 40:658. [PubMed: 19461840]
18. Adams PD, Afonine PV, Bunkóczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW, McCoy AJ, Moriarty NW, Oeffner R, Read RJ, Richardson DC, Richardson JS, Terwilliger TC, Zwart PH. *Acta Crystallogr. D.* 2010; 66:213. [PubMed: 20124702]
19. Luzzati PV. *Acta Crystallogr.* 1952; 5:802.
20. Smith GD, Blessing RH, Ealick SE, Fontecilla-Camps JC, Hauptman HA, Housset D, Langs DA, Miller R. *Acta Crystallogr. D.* 1997; 53:551. [PubMed: 15299886]
21. Karbat I, Frolow F, Froy O, Gilles N, Cohen L, Turkov M, Gordon D, Gurevitz M. *J. Biol. Chem.* 2004; 279:31679. [PubMed: 15133045]
22. Selvin PR. *Annu. Rev. Biophys. Biomol. Struct.* 2002; 31:275. [PubMed: 11988471]
23. Kubota T, Brugarolas P, Dang B, Finolurdaneta RK, Frezza L, French RJ, Kent SBH, Bezanilla F, Correa AM. *Biophysical Journal.* 2014; 106:133a.

a Residue #1-Residue #61:
 KKDGYPVEYD NCAYICWNYD NAY**CD**KLCKD³⁰
 KKADSGYCYW VHIL**CY**CYGL PDSEPTKTNG⁶⁰ K-


Four C-terminus candidates:

Ts3(1-62) -C⁶²-COOH

Ts3(1-64) -CKS⁶⁴-CONH₂

Ts3(1-66) -CKSGK⁶⁶-COOH

Ts3(1-67) -CKSGKK⁶⁷-COOH



Scheme 1.


Candidate amino acid sequences for the Ts3 polypeptide chain and synthetic strategy for their preparation. a) Sequences of candidate Ts3 polypeptide chains.^[9,10] b) Modular synthetic strategy based on native chemical ligation for preparation of the four candidate Ts3 polypeptide chains. ‘C-terminus’ is one of the four candidates listed in scheme 1a.

```

Ts1:  KEGYLMDHEGCKLSCFIRPSGYCGRECGIKKGSSGYCAWP
Ts3:  KKDGPVEYDNCAYICWNYDNAYCDKLCKDKKADSGYCYWV
      1      10      20      30      40
Ts1:  --ACYCYGLPNWVKVWDRATNKC
Ts3:  HILCYCYGLPDSEPTKTNG--KC (KSGKK)
                50      60

```

Figure 1. Comparison of the amino acid sequences of Ts3 and Ts1 toxins. Alignment based on Cys residues (bold); conserved amino acids underlined. Until now, the presence in mature biologically active Ts3 protein of the C-terminal residues enclosed in parentheses was in dispute.






Figure 2.

Chemical synthesis of Ts3 (1-64)- $CONH_2$ protein. a) Analytical LCMS data for the synthesis of polypeptide Lys¹-Ser⁶⁴- $CONH_2$. **1** Thz²⁴-Ser⁶⁴- $CONH_2$; **2** Cys⁴⁷-Ser⁶⁴- $CONH_2$; **3** Cys²⁴-Ser⁶⁴- $CONH_2$; **4** Lys¹-Tyr²³- COS thiolactone; **5** Desired product Lys¹-Ser⁶⁴- $CONH_2$. b) Analytical HPLC data for folding/disulfides formation of crude Ts3(1-64)- $CONH_2$ polypeptide. Folding conditions: [polypeptide] 0.02 mg/mL; 2.0 mM GSH/1.0 mM GSSG; 0.5 M L-arginine-HCl; 1 mM EDTA; 0.1 M Tris, 20% DMSO pH 8.5; room temperature. Analytical LCMS conditions are described in the SI.








Figure 3. Biological activities of Ts3 protein candidates. a) Disruption of rNa_v1.4 fast inactivation compared among the 4 different candidate Ts3 proteins. Na⁺ ionic current, elicited by a step-pulse to -10 mV from a holding potential of -90 mV, was measured without (blue traces) and with (red traces) 210 nM of each candidate protein. b) Dose-response assay of rNa_v1.4 fast inactivation modification by Ts3(1-64)-CONH₂ protein. The right panel shows the proportion of the slower component of the fit as a function of toxin concentration. Error bars indicate standard error of the mean (number of cells = 3-6 cells).







d




Figure 4. Crystal structure of Ts3(1-64)-*CONH*₂ toxin protein. a) Crystal structure of the D/L racemate of Ts3(1-64)-*CONH*₂ protein, (PDB 5CY0). Cartoon representation of the packing of D-Ts3(1-64)-*CONH*₂ (Cyan) and L-Ts3(1-64)-*CONH*₂ (Green) proteins in the unit cell in P1$\bar{3}$. b) Structure alignment of Ts3 toxin (green) and alpha scorpion toxin LQH- α -IT (golden) and Aah2 (magenta).^[20] c) Core domain hydrophobic surface comparison between Ts3 and other alpha scorpion toxins. d) NC-domain comparison between Ts3 and other alpha scorpion toxins. e) Hydrogen bonding of Asn11 and Lys57 with residues in the C-terminal region of Ts3.